Concerns regarding the safety of azithromycin in pregnancy - relevance for women with cystic fibrosis

Jennifer L. Taylor-Cousar, Raksha Jain, Tracy M. Kazmerski, Moira L. Aitken, Natalie E. West, Alexandra Wilson, Peter G. Middleton, Edward F. Nash

Research output: Contribution to journalLetter

Abstract

Chronic oral azithromycin therapy improves clinical outcomes in people with cystic fibrosis (CF), and is recommended for treatment of CF lung disease. Azithromycin is categorized as pregnancy class B. The data for risk of congenital malformations associated with use of azithromycin during pregnancy ranges from no risk to a small increased risk. As with other chronic medications used to treat CF, potential risk to the infant of use of azithromycin during pregnancy must be weighed against the potential risk to the mother of treatment discontinuation. Women with CF considering pregnancy while on chronic azithromycin should be counseled regarding potential risks and benefits.

Original languageEnglish (US)
JournalJournal of Cystic Fibrosis
DOIs
StateAccepted/In press - 2020

Keywords

  • Azithromycin
  • Congenital malformations
  • Macrolide
  • Pregnancy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Concerns regarding the safety of azithromycin in pregnancy - relevance for women with cystic fibrosis'. Together they form a unique fingerprint.

Cite this